Boehringer Ingelheim Opens New R&D Facility
Boehringer Ingelheim has announced the opening of their new advanced Biologics Development Center (BDC) in Biberach an der Riß, Germany. To bring this development to life, the company invested €350m, representing its largest single investment in the country to date.
The new high-tech facility is set to strengthen the company’s biopharmaceuticals development capabilities which account for approximately 50% of the company’s research pipeline. The facility stands at 34,500 m2 with workspace for over 500 employees, supporting the research of several disciplines and three entire development units focused on researching antibodies and therapeutic proteins.
As of 2018, Boehringer Ingelheim is one of the world’s largest pharmaceutical companies, and the largest private one. The research-driven company is committed to sustainable development, ensuring sustainability throughout the value chain.
The company plans to continue supporting this high level, sustainable research through the constant investment in their broad pipeline of research activities. This past January, the US Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets to treat adult patients with chronic kidney disease.
Who We Are:
Research and development is the engine of economic growth in an increasingly knowledge-based global economy, however more investment is needed to help boost human creativity, innovation and economic output.
Swanson Reed is one of Germany’s largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
To find out more about R&D or to determine the eligibility of your business for receiving an R&D tax credit, contact a Swanson Reed R&D Tax Advisor today.
